uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting
European Ctr Dis Prevent & Control ECDC, Stockholm, Sweden.
NHS Blood & Transplant, Natl Transfus Microbiol Reference Lab, London, England;Publ Hlth England, London, England.
Belgian Red Cross Flanders, Transfus Res Ctr, Ghent, Belgium.
European Ctr Dis Prevent & Control ECDC, Stockholm, Sweden.
Show others and affiliations
2019 (English)In: Blood Transfusion, ISSN 1723-2007, Vol. 17, no 6, p. 433-448Article in journal (Refereed) Published
Abstract [en]

Pathogen reduction (PR) of selected blood components is a technology that has been adopted in practice in various ways. Although they offer great advantages in improving the safety of the blood supply, these technologies have limitations which hinder their broader use, e.g. increased costs. In this context, the European Centre for Disease Prevention and Control (ECDC), in co-operation with the Italian National Blood Centre, organised an expert consultation meeting to discuss the potential role of pathogen reduction technologies (PRT) as a blood safety intervention during outbreaks of infectious diseases for which (in most cases) laboratory screening of blood donations is not available. The meeting brought together 26 experts and representatives of national competent authorities for blood from thirteen European Union and European Economic Area (EU/EEA) Member States (MS), Switzerland, the World Health Organization, the European Directorate for the Quality of Medicines and Health Care of the Council of Europe, the US Food and Drug Administration, and the ECDC. During the meeting, the current use of PRTs in the EU/EEA MS and Switzerland was verified, with particular reference to emerging infectious diseases (see Appendix). In this article, we also present expert discussions and a common view on the potential use of PRT as a part of both preparedness and response to threats posed to blood safety by outbreaks of infectious disease.

Place, publisher, year, edition, pages
SIMTIPRO SRL , 2019. Vol. 17, no 6, p. 433-448
Keywords [en]
pathogen reduction technologies, blood safety, infectious diseases outbreaks, blood components
National Category
Hematology
Identifiers
URN: urn:nbn:se:uu:diva-401184DOI: 10.2450/2019.0288-19ISI: 000502555900007PubMedID: 31846608OAI: oai:DiVA.org:uu-401184DiVA, id: diva2:1383079
Available from: 2020-01-07 Created: 2020-01-07 Last updated: 2020-01-07Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Knutson, Folke

Search in DiVA

By author/editor
Knutson, Folke
By organisation
Clinical Immunology
In the same journal
Blood Transfusion
Hematology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 3 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf